Multiple Doses of UCB4940 In Subjects With Psoriatic Arthritis
Research type
Research Study
Full title
A SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE DOSES OF UCB4940 IN SUBJECTS WITH PSORIATIC ARTHRITIS
IRAS ID
147699
Contact name
Abdelrazig Salih
Contact email
Eudract number
2013-004949-16
Research summary
UCB is developing a drug known as UCB4940 for the treatment of psoriatic arthritis (PsA). Single doses of the study drug have so far been tested in one study, which involved 39 subjects.
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of multiple doses of the study drug in subjects with psoriatic arthritis.
There will also be an additional sub-study within this study. This additional sub-study is designed to add information on genomics and pharmacogenomics to the main study.
This study will involve at least 50 subjects across 3 centres throughout Europe.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
14/NW/0032
Date of REC Opinion
12 Mar 2014
REC opinion
Further Information Favourable Opinion